Home Healthcare Pharmaceuticals Asia Pacific Neurodegenerative Disease Market

Asia Pacific Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Asia Pacific Neurodegenerative Disease Market Size Analysis
    1. Introduction
    2. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Multiple Sclerosis
      2. Parkinson's Disease
      3. Alzheimer's Disease
      4. Others
    3. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Immunomodulator
      2. Vesicular Monoamine Transporter 2 (VMAT2)
      3. Others
    4. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Intravenous (IV) delivery
      3. Others
  7. APAC Asia Pacific Neurodegenerative Disease Market Size Analysis
    1. Introduction
    2. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Multiple Sclerosis
      2. Parkinson's Disease
      3. Alzheimer's Disease
      4. Others
    3. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Immunomodulator
      2. Vesicular Monoamine Transporter 2 (VMAT2)
      3. Others
    4. Asia Pacific Neurodegenerative Disease Market Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Intravenous (IV) delivery
      3. Others
    5. China
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    8. India
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      3. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      4. Market Size & Forecast By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
  8. Competitive Landscape
    1. Asia Pacific Neurodegenerative Disease Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  9. Market Players Assessment
    1. Sun Pharmaceutical Industries Limited
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Wockhardt Ltd.
  10. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  11. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  12. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.